The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.43
Bid: 1.43
Ask: 1.45
Change: 0.00 (0.00%)
Spread: 0.02 (1.399%)
Open: 1.42
High: 1.43
Low: 1.42
Prev. Close: 1.43
RTW Live PriceLast checked at -
RTW Venture is an Investment Trust

To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Publication of Circular & Convening of EGM

1 Dec 2022 07:00

RNS Number : 1152I
RTW Venture Fund Limited
01 December 2022
 

LEI: 549300Q7EXQQH6KF7Z84

1 December 2022

RTW Venture Fund Limited

Publication of Circular & Convening of EGM

Further to the announcement on 28 November 2022, RTW Venture Fund Limited (the "Company") announces that documentation has been filed with the U.S. Internal Revenue Service to change the Company's tax status, with effect from 1 December 2022, from a "publicly traded partnership" or "PTP" to a corporation for U.S. federal tax purposes ("Tax Election").

A shareholder circular (the "Circular") has been published today on the Company's website at www.rtwfunds.com/venture-fund. In addition,  a copy of the Circular has been submitted to the National Storage Mechanism and will shortly be available for viewing online at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

A notice of an Extraordinary General Meeting ("EGM") is contained in the Circular. At the EGM, Shareholders will be asked (a) to approve the adoption of new articles of incorporation, which will be updated to reflect the U.S. federal tax status of the Company following completion of the Tax Election and the reorganisation; and (b) to ratify the decision of the Board to make the Tax Election.

This information is not intended to be all-inclusive or to render specific professional tax advice. Shareholders are urged to consult with their independent tax advisors to determine the tax consequences. The Company does not provide tax or legal advice.

For Further Information:

RTW Investments, LP

+44 (0) 77 1741 7711

Woody Stileman, Managing Director

Buchanan

+44 (0)20 7466 5107

Charles Ryland

Henry Wilson

George Beale

J.P. Morgan Cazenove

+44 (0)20 7742 4000

William Simmonds

Jérémie Birnbaum

James Bouverat (Sales)

BofA Securities

+44 (0) 20 7628 1000

Edward Peel

Kieran Millar

Elysium Fund Management Limited

+44 (0) 14 8181 0100

Joanna Duquemin Nicolle, Chief Executive Officer

Sadie Morrison, Managing Director

Morgan Stanley Fund Services USA LLC

+1 (914) 225 8885

 

 

About RTW Venture Fund Limited:

RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives.

RTW Venture Fund Limited is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the RTW website at www.rtwfunds.com for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFDDFDSEESEDF
Date   Source Headline
27th Apr 202011:40 amRNSIssue of Equity
27th Apr 20207:00 amRNSAnnouncement of further Share Issuance
24th Apr 20206:27 pmRNSIssue of Equity
23rd Apr 20207:00 amRNSAnnouncement of Share Issuance
22nd Apr 20207:01 amRNSPerformance Allocation Share Distribution Deferral
22nd Apr 20207:00 amRNSAnnual Report and Audited Financial Statements
20th Apr 20207:00 amRNSDirector/PDMR Shareholding
17th Apr 20207:00 amRNSQuarterly Update
15th Apr 20206:22 pmRNSNet Asset Value(s)
9th Apr 20204:22 pmRNSNotice of Annual Report
1st Apr 20206:00 pmRNSSeries B2 Financing in iTeos Therapeutics
1st Apr 20204:00 pmRNSName Change of Administrator and Company Secretary
18th Mar 202012:23 pmRNSDirector/PDMR Shareholding
18th Mar 202011:56 amRNSDirector/PDMR Shareholding
13th Mar 20207:00 amRNSNet Asset Value(s)
2nd Mar 20207:00 amRNSTotal Voting Rights
26th Feb 20207:00 amRNSIssue of Equity
19th Feb 20207:00 amRNSIssue of Equity
17th Feb 20205:10 pmRNSAnnouncement of Share Issuance
14th Feb 20207:00 amRNSNet Asset Value(s)
3rd Feb 20207:00 amRNSTotal Voting Rights
29th Jan 20207:00 amRNSIssue of Equity
27th Jan 20207:00 amRNSIssue of Equity
17th Jan 20204:30 pmRNSIssue of Equity
16th Jan 20207:00 amRNSIssue of Equity
15th Jan 20207:00 amRNSNet Asset Value(s)
23rd Dec 201911:28 amRNSHolding(s) in Company
16th Dec 20195:57 pmRNSNet Asset Value(s)
21st Nov 20193:45 pmRNSRTW leads $100M Financing in Avidity Biosciences
5th Nov 201910:00 amRNSHolding(s) in Company
5th Nov 20199:44 amRNSHolding(s) in Company
1st Nov 20197:00 amRNSTotal Voting Rights
30th Oct 20193:16 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.